The Technical Analyst
Cerecor Inc [CERC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cerecor Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.68% $2.93
America/New_York / 26 aug 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 38.63 mill |
| EPS: | -0.867 |
| P/E: | -3.38 |
| Earnings Date: | Aug 02, 2021 |
| SharesOutstanding: | 13.18 mill |
| Avg Daily Volume: | 0.639 mill |
| RATING 2021-08-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.38 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.57x |
| Company: PE -3.38 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.76 - 3.10 ( +/- 5.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-08-18 | Armistice Capital, Llc | Buy | 20 000 | Common Stock |
| 2021-08-16 | Armistice Capital, Llc | Buy | 30 000 | Common Stock |
| 2021-07-01 | Cola Michael F | Buy | 51 740 | Stock Option (Right to Buy) |
| 2021-06-30 | Bruhn Suzanne Louise | Buy | 3 465 | Stock Option (Right to Buy) |
| 2021-06-30 | Kaplan Gilla | Buy | 6 353 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 95 transactions |
| Buy: 9 414 351 | Sell: 408 195 |
Forecast:
01:40 - $3.07
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.93 (-1.68% ) |
| Volume | 0.259 mill |
| Avg. Vol. | 0.639 mill |
| % of Avg. Vol | 40.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CERC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CERC
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Latest Press Releases
2021-08-26 07:30:00 - Press Release
Avalo Therapeutics, Inc. Announces Corporate Name Change From Cerecor Inc.
Wayne, pa. and rockville, md., aug. 26, 2021 (globe newswire) -- avalo therapeutics, inc. (nasdaq: avtx), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that it has launched its new corporate name avalo therapeutics, inc. this new name reflects the company's dedication to helping address the significant unmet medical need for patients, as well as to align with the forward momentum of its large and promising pipeline of potential first-in-class therapeutic candidates. in conjunction with the corporate name change, the company will trade on the nasdaq capital market under the new ticker symbol "avtx"...
2021-08-02 16:01:00 - Press Release
Cerecor Reports Second Quarter 2021 Financial Results And Provides Business Updates
Rockville, md. and chesterbrook, pa., aug. 02, 2021 (globe newswire) -- cerecor inc. (nasdaq: cerc), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced recent business progress and second quarter 2021 financial results.
2021-08-02 07:30:00 - Press Release
Cerecor Announces Drawdown Of $10 Million Tranche Under Its Debt Financing Agreement With Horizon Technology Finance
Achieved performance milestone with positive initial results from its phase 1b trial of cerc-002 in moderate-to- severe crohn's disease who had previously failed three or more lines of biologics therapies, including anti-tnf alpha treatments achieved performance milestone with positive initial results from its phase 1b trial of cerc-002 in moderate-to- severe crohn's disease who had previously failed three or more lines of biologics therapies, including anti-tnf alpha treatments
2021-06-23 07:30:00 - Press Release
Cerecor Licenses Immune Checkpoint Program From Sanford Burnham Prebys Further Expanding Pipeline Of Immunology And Immuno-oncology Targets
Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders
2021-03-08 16:01:00 - Press Release
Cerecor Reports 2020 Financial Results And Provides Business Updates
Rockville, md. and chesterbrook, pa., march 08, 2021 (globe newswire) -- cerecor inc. (nasdaq: cerc), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and year-end financial results for 2020.
Latest News
2021-08-26 07:30:00 - GlobeNewsWire
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that it has launched its new corporate name Avalo Therapeutics, Inc. This new name reflects the Company's dedication to helping address the significant unmet medical need for patients, as well as to align with the forward momentum of its large and promising pipeline of potential first-in-class therapeutic candidates. In conjunction with the corporate name change, the Company will trade on the Nasdaq Capital Market under the new ticker symbol "AVTX"...
2021-08-02 16:01:00 - GlobeNewsWire
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced recent business progress and second quarter 2021 financial results.
2021-08-02 07:30:00 - GlobeNewsWire
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments
2021-07-27 06:16:28 - Benzinga
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
Cerecor Inc (NASDAQ: CERC) announced initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease (CD). CERC-002 is an investigational fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (TNFSF14)) monoclonal antibody.
2021-06-23 07:30:00 - GlobeNewsWire
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders
2021-05-11 09:27:00 - PennyStocks
Top Penny Stocks to Buy Moving in Premarket? Check These 3 Out
These 3 penny stocks made big moves in pre-market trading; are they worth it? The post Top Penny Stocks to Buy Moving in Premarket?
2021-05-11 09:15:19 - Benzinga
Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients
The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14).
2021-05-11 07:33:21 - Market Watch
Cerecor's investigational COVID-19 therapy gets Fast Track designation from the FDA
Shares of Cerecor Inc. gained 17.3% in premarket trading on Tuesday after the company said its experimental COVID-19 drug had received a Fast Track designation from the Food and Drug Administration. The treatment candidate is a monoclonal antibody being targeted at people with COVID-19 who are sick enough to be hospitalized.
2021-04-30 10:10:10 - InvestorPlace
A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout
$230 million biopharmaceutical company Cerecor (CERC) may end up being the industry's biggest winner on Wall Street over the next six months. The post A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout appeared first on InvestorPlace.
2021-03-29 08:33:13 - Benzinga
Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002
Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has entered into an expanded agreement with Kyowa Kirin Co Ltd (OTCMKTS: KYKOF) for exclusive worldwide rights to CERC-002 for all indications, including severe pediatric-onset inflammatory bowel disease and ARDS (including COVID-19 ARDS). Under the terms of the agreement, Cerecor will receive exclusive rights for the development, manufacturing, and commercialization of the antibody for all indications worldwide, including the U.S., Europe, and Japan.